Zargis Signs Exclusive Pact With Johns Hopkins University
November 12 2004 - 8:00AM
PR Newswire (US)
Zargis Signs Exclusive Pact With Johns Hopkins University
PRINCETON, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Zargis Medical
Corp., a majority-owned subsidiary of Speedus Corp. (NASDAQ:SPDE),
announced today it has signed an exclusive agreement with Johns
Hopkins University and its Applied Physics Laboratory. The
agreement will give Zargis exclusive commercial rights to JHU's
signal processing algorithms, certain patents including "System and
Method for Diagnosing Pathologic Heart Conditions", patent
applications and other intellectual property, including an
extensive cardiac research database of more than 6,500 recordings
from over 1,200 individuals. This collaboration between Zargis and
JHU will not only enable Zargis to expedite its product development
pipeline in this field, but also accelerate any potential clinical
adoption through association with one of the world's leading
medical research centers. The agreement will also provide access to
JHU's outstanding clinical and scientific staff who will supplement
Zargis' research and development capabilities to enhance and
develop future products. "This work is a natural follow-on to
signal processing techniques and algorithms we have developed for
detecting and classifying submarines and we are very excited to be
working with the research and clinical teams at Zargis," commented
Physicist Scott Hayek from the Applied Physics Lab of Johns Hopkins
University. According to John Kallassy, Managing Director of
Zargis, "This agreement furthers Zargis' current leadership
position in computer-assisted heart sound analysis which has the
potential to both improve the quality of patient care and reduce
the costs associated with unnecessary referrals." About Johns
Hopkins University and Applied Physics Laboratory The Applied
Physics Laboratory, a division of The Johns Hopkins University,
meets critical national challenges through the innovative
application of science and technology. For information, visit
http://www.jhuapl.edu/. The Johns Hopkins University School of
Medicine strives to provide international leadership in the
education of physicians and medical scientists, in biomedical
research, and in the application of medical knowledge to patient
care. For information, visit http://www.hopkinsmedicine.org/. About
Zargis Medical Corp. Zargis Medical Corp. was formed in January
2001 when Siemens Corporate Research Inc., a subsidiary of Siemens
AG (NYSE:SI), and Speedus Corp. (NASDAQ:SPDE) co-invested in Zargis
to further develop and commercially market an advanced acoustic
technology for detecting abnormalities identified through analysis
of heart sounds. Based in Princeton, New Jersey, Zargis is
developing advanced diagnostic decision support products and
services for primary care physicians, pediatricians, cardiologists
and other healthcare professionals. Zargis has developed
Cardioscan, the first and only FDA approved computer- assisted
medical device to support physicians in analyzing heart sounds for
the identification of suspected murmurs, a potential sign of heart
disease. Cardioscan is easy to use, non-invasive, portable, and
takes just minutes to perform. Developed by scientists from Siemens
and Zargis over many years, Cardioscan implements voice-guided
protocol and graphical user interface while maintaining an
efficient physician workflow. The system provides a summary of
findings in terms that are readily understood by physicians with
more quantitative auscultatory information than is possible through
listening alone. Thus, Cardioscan enhances auscultation which has
been universally employed through a stethoscope for nearly two
hundred years. For additional information on Speedus Corp. or
Zargis Medical, contact John Kallassy, 718.567.4358, , or visit
their websites at http://www.speedus.com/ and
http://www.zargis.com/. For additional information on Siemens
Corporate Research, visit their website at
http://www.scr.siemens.com/. Statements contained herein that are
not historical facts, including but not limited to statements about
the Company's product, corporate identity and focus, may be
forward-looking statements that are subject to a variety of risks
and uncertainties. There are a number of important factors that
could cause actual results to differ materially from those
expressed in any forward- looking statements made by the Company,
including, but not limited to, the continuing development of the
Company's sales, marketing and support efforts. DATASOURCE: Zargis
Medical Corp. CONTACT: John Kallassy, +1-718-567-4358, or Web site:
http://www.speedus.com/ http://www.zargis.com/
http://www.jhuapl.edu/. http://www.hopkinsmedicine.org/
http://www.scr.siemens.com/
Copyright
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Jul 2023 to Jul 2024